Research Summary

Dr. Shawn Hervey-Jumper is a neurosurgeon with subspecialty focus on neuro-oncology. His clinical practice is focused on the surgical management of patients with brain cancer within functional areas using physiological mapping. Dr. Hervey-Jumper's research focuses on the mechanisms by which intrinsic brain tumors, such as low- and high-grade gliomas, interface with neural networks and how repair of these networks impacts cognition. Though the survival of some may be short, it is increasingly understood that many glioma patients will survive for years with extensive language, motor, and cognitive disabilities that impact the quality of their lives. Despite the prevailing assumption that gliomas represent an ablative process, we now know that interactions between glioma cells and the neuronal microenvironment influence tumor growth, invasiveness, and potentially cognition. In his research laboratory he uses neurophysiology in order to address questions in human cognition as well as tumor-network dynamics.

Research Funding

  • May 1, 2019 - April 30, 2024 - Intratumoral functional connectivity with implications on synaptogenesis and aphasia recovery in adult astrocytic WHO II-III glioma , Principal Investigator . Sponsor: NINDS, Sponsor Award ID: 1K08NS110919-01
  • February 1, 2018 - February 28, 2023 - IDH1 Mutant Glioma Model: Tumor Progression and Impact on Therapeutics , Co-Investigator . Sponsor: NINDS, Sponsor Award ID: P0523121
  • July 1, 2017 - July 1, 2021 - The consequences of brain irradiation on white matter repair and language pathways reorganization in adult glioma , Principal Investigator . Sponsor: Robert Wood Johnson Foundation, Sponsor Award ID: 74259
  • July 1, 2017 - June 30, 2020 - Neurogenesis mediated Aphasia Recovery in Adult High Grade Glioma , Principal Investigator . Sponsor: University of California San Francisco, Sponsor Award ID: Dean's Diversity Fund

Education

Oakwood College, Huntsville, AL, B.S., 05/2001, Biology
The Ohio State University, Columbus, OH, M.D., 06/2006,Medicine
University of Michigan, Ann Arbor, MI, Internship, 06/2007, Transitional
University of Michigan, Ann Arbor, MI, Research Fellowship, 01/2012, Neuro-Oncology
University of Michigan, Ann Arbor, MI, Resident, 06/2012, Neurosurgery
University of Michigan, Ann Arbor, MI, Chief Resident, 06/2013, Neurosurgery
University of California San Francisco, SF, CA, Clinical Fellowship, 06/2014, Neuro-Oncology

Honors & Awards

  • 2005
    Alpha Omega Alpha Medical Honors Society, Ohio State University
  • 2005
    Gold Humanism Honor Society, The Ohio State University
  • 2006
    Landacre Research Honors Society, Ohio State University
  • 2006
    Watchman Achievement Award, Alpha Omega Alpha Medical Honors Society
  • 2007
    National Scholars Honor Society, The Ohio State University
  • 2007
    Arnold G. Coran Teaching Award, University of Michigan
  • 2010
    Health Policy Scholar, Ruben J Williams (RJW) Foundation
  • 2011
    Wilder Penfield Award, Congress of Neurological Surgeons
  • 2011
    NREF/AAcNS Research Award
  • 2013
    Chandler-McGillicuddy leadership award, University of Michigan
  • 2013
    Max Peet Teaching Award, University of Michigan
  • 2014
    Ronald L. Bittner Award in Brain Tumor Research, AANS/CNS Section on Tumors
  • 2016
    Alfred Taubman Medical Research Institute Emerging Scholar
  • 2017
    Robert Wood Johnson Foundation Harold Amos Fellow
  • 2017
    John A. Watson Faculty Scholar
  • 2022
    Weill Award for Clinician-Scientists in the Neurosciences

Selected Publications

  1. Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro Oncol. 2023 Sep 05; 25(9):1672-1685.  View on PubMed
  2. Young JS, Morshed RA, Hervey-Jumper SL, Berger MS. The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions. Neuro Oncol. 2023 Jul 27.  View on PubMed
  3. Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC, Bush NAO, Hervey-Jumper SL, Klein OD, Toedebusch CM, Horbinski CM, Magill ST, Bhaduri A, Perry A, Dickinson PJ, Heimberger AB, Ashworth A, Crouch EE, Raleigh DR. NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy. bioRxiv. 2023 Jul 11.  View on PubMed
  4. Young JS, Al-Adli NN, Muster R, Chandra A, Morshed RA, Pereira MP, Chalif EJ, Hervey-Jumper SL, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK. Does waiting for surgery matter? How time from diagnostic MRI to resection affects outcomes in newly diagnosed glioblastoma. J Neurosurg. 2023 Jun 23; 1-14.  View on PubMed
  5. Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol. 2023 05 04; 25(5):940-954.  View on PubMed
  6. Krishna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, Lee A, Aabedi A, Popova G, Lipkin B, Cao C, Nava Gonzales C, Sudharshan R, Egladyous A, Almeida N, Zhang Y, Molinaro AM, Venkatesh HS, Daniel AGS, Shamardani K, Hyer J, Chang EF, Findlay A, Phillips JJ, Nagarajan S, Raleigh DR, Brang D, Monje M, Hervey-Jumper SL. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023 May; 617(7961):599-607.  View on PubMed
  7. Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, Gutmann DH, Hervey-Jumper S, Kuner T, Mabbott D, Platten M, Rolls A, Sloan EK, Wang TC, Wick W, Venkataramani V, Monje M. Cancer neuroscience: State of the field, emerging directions. Cell. 2023 04 13; 186(8):1689-1707.  View on PubMed
  8. Hollon TC, Golfinos JG, Orringer DA, Berger M, Hervey-Jumper SL, Muraszko KM, Freudiger C, Heth J, Sagher O, Jiang C, Chowdury A, Moin MN, Kondepudi A, Aabedi AA, Adapa AR, Al-Holou W, Wadiura L, Widhalm G, Neuschmelting V, Reinecke D, Camelo-Piragua S. 102 AI-Based Molecular Classification of Diffuse Gliomas using Rapid, Label-Free Optical Imaging. Neurosurgery. 2023 04 01; 69(Suppl 1):22-23.  View on PubMed
  9. Tang LW, Mallela AN, Deng H, Richardson TE, Hervey-Jumper SL, McBrayer SK, Abdullah KG. Preclinical modeling of lower-grade gliomas. Front Oncol. 2023; 13:1139383.  View on PubMed
  10. Hollon T, Jiang C, Chowdury A, Nasir-Moin M, Kondepudi A, Aabedi A, Adapa A, Al-Holou W, Heth J, Sagher O, Lowenstein P, Castro M, Wadiura LI, Widhalm G, Neuschmelting V, Reinecke D, von Spreckelsen N, Berger MS, Hervey-Jumper SL, Golfinos JG, Snuderl M, Camelo-Piragua S, Freudiger C, Lee H, Orringer DA. Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging. Nat Med. 2023 04; 29(4):828-832.  View on PubMed
  11. Scott AJ, Correa LO, Edwards D, Sun Y, Ravikumar V, Andren AC, Zhang L, Srinivasan S, Jairath N, Verbal K, Muraszko K, Sagher O, Carty SA, Hervey-Jumper S, Orringer D, Kim MM, Junck L, Umemura Y, Leung D, Venneti S, Camelo-Piragua S, Lawrence TS, Ippolito JE, Al-Holou WN, Chinnaiyan P, Heth J, Rao A, Lyssiotis CA, Wahl DR. Metabolomic profiles of human glioma inform patient survival. Antioxid Redox Signal. 2023 Feb 27.  View on PubMed
  12. Morshed RA, Nguyen MP, Cummins DD, Saggi S, Young JS, Haddad AF, Goldschmidt E, Chang EF, McDermott MW, Berger MS, Theodosopoulos PV, Hervey-Jumper SL, Daras M, Aghi MK. CDKN2A/B co-deletion is associated with increased risk of local and distant intracranial recurrence after surgical resection of brain metastases. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad007.  View on PubMed
  13. Morshed RA, Saggi S, Cummins DD, Molinaro AM, Young JS, Viner JA, Villanueva-Meyer JE, Goldschmidt E, Boreta L, Braunstein SE, Chang EF, McDermott MW, Berger MS, Theodosopoulos PV, Hervey-Jumper SL, Aghi MK, Daras M. Identification of risk factors associated with leptomeningeal disease after resection of brain metastases. J Neurosurg. 2023 Jan 13; 1-12.  View on PubMed
  14. Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, Lafontaine M, Luks T, Ammanuel S, Kakaizada S, Egladyous A, Gogos A, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Crane J, Wrensch M, Wiencke JK, Daras M, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Jakola AS, Kavouridis VK, Nawabi N, Solheim O, Smith T, Berger MS, Molinaro AM. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol. 2023 04 10; 41(11):2029-2042.  View on PubMed
  15. Forster MT, De Witt Hamer P, Hervey-Jumper SL, Renovanz M. Corrigendum: Editorial: Quality of care of glioma patients. Front Neurol. 2022; 13:1084412.  View on PubMed
  16. Zhang JJY, Lee KS, Wang DD, Hervey-Jumper SL, Berger MS. Seizure outcome after resection of insular glioma: a systematic review, meta-analysis, and institutional experience. J Neurosurg. 2023 05 01; 138(5):1242-1253.  View on PubMed
  17. Forster MT, De Witt Hamer P, Hervey-Jumper SL, Renovanz M. Editorial: Quality of care of glioma patients. Front Neurol. 2022; 13:1041388.  View on PubMed
  18. Taylor JW, Weyer-Jamora C, Hervey-Jumper S. Molecularly determining cognition in glioma: New insights as the plot thickens. Neuro Oncol. 2022 10 03; 24(10):1671-1672.  View on PubMed
  19. Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022 10 03; 24(10):1749-1762.  View on PubMed
  20. Karschnia P, Young JS, Dono A, Häni L, Juenger ST, Sciortino T, Bruno F, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, van den Bent M, Weller M, Berger MS, Chang SM, Tonn JC. TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac158.  View on PubMed

Go to UCSF Profiles, powered by CTSI